Artivion (AORT)
Artivion on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus.
3.7M
Short interest
settlement 2026-10-15
7.2
Days to cover
+1.7 days vs prior
56.8%
Short share of volume
2026-11-03
61
Fails to deliver
settlement 2026-10-09
Thu 5 Nov
Next earnings
estimated date
-$2.6M
Insider flow, 90 days
0 buys, 7 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in AORT is 3,735,523 shares, up 451,325 shares over the last month. Over the last 48 readings it ranged from 995,912 shares (15 August 2025) to 4,337,827 shares (15 May 2025). At the reported average volume of 517K shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/aort" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,735,523 | +3.1% | 517,233 | 7.22 |
| 2026-09-30 | 3,621,461 | +10.3% | 654,874 | 5.53 |
| 2026-09-15 | 3,284,198 | +12.2% | 604,535 | 5.43 |
| 2026-08-31 | 2,927,038 | +6.6% | 662,170 | 4.42 |
| 2026-08-14 | 2,745,747 | +1.5% | 857,370 | 3.20 |
| 2026-07-31 | 2,705,501 | +8.3% | 568,148 | 4.76 |
| 2026-07-15 | 2,498,637 | +14.6% | 550,079 | 4.54 |
| 2026-06-30 | 2,179,918 | +15.4% | 1,075,389 | 2.03 |
| 2026-06-15 | 1,888,924 | -1.5% | 810,012 | 2.33 |
| 2026-05-29 | 1,917,337 | -1.3% | 679,115 | 2.82 |
| 2026-05-15 | 1,942,065 | +1.1% | 1,140,219 | 1.70 |
| 2026-04-30 | 1,920,829 | -1.2% | 303,547 | 6.33 |
| 2026-04-15 | 1,943,835 | +16.6% | 523,130 | 3.72 |
| 2026-03-31 | 1,667,100 | -0.4% | 389,108 | 4.28 |
| 2026-03-13 | 1,674,278 | +6.3% | 396,231 | 4.23 |
| 2026-02-27 | 1,575,745 | +13.6% | 568,701 | 2.77 |
| 2026-02-13 | 1,386,551 | -15.4% | 489,962 | 2.83 |
| 2026-01-30 | 1,638,404 | +2.6% | 312,918 | 5.24 |
| 2026-01-15 | 1,596,695 | +12.6% | 291,741 | 5.47 |
| 2025-12-31 | 1,418,454 | +18.9% | 363,950 | 3.90 |
| 2025-12-15 | 1,193,038 | -0.1% | 356,351 | 3.35 |
| 2025-11-28 | 1,194,637 | -5.8% | 336,355 | 3.55 |
| 2025-11-14 | 1,268,743 | -8.1% | 500,639 | 2.53 |
| 2025-10-31 | 1,380,204 | +4.9% | 350,551 | 3.94 |
| 2025-10-15 | 1,315,327 | -2.3% | 271,844 | 4.84 |
| 2025-09-30 | 1,346,234 | +24.1% | 506,460 | 2.66 |
| 2025-09-15 | 1,084,337 | -0.8% | 400,343 | 2.71 |
| 2025-08-29 | 1,092,649 | +9.7% | 454,143 | 2.41 |
| 2025-08-15 | 995,912 | -17.6% | 759,350 | 1.31 |
| 2025-07-31 | 1,208,000 | -11.3% | 286,558 | 4.22 |
| 2025-07-15 | 1,361,182 | -4.5% | 343,579 | 3.96 |
| 2025-06-30 | 1,425,190 | -6.5% | 384,183 | 3.71 |
| 2025-06-13 | 1,523,931 | -3.7% | 288,542 | 5.28 |
| 2025-05-30 | 1,582,050 | -63.5% | 379,014 | 4.17 |
| 2025-05-15 | 4,337,827 | +20.3% | 688,152 | 6.30 |
| 2025-04-30 | 3,605,010 | +2.2% | 313,263 | 11.51 |
| 2025-04-15 | 3,528,302 | -5.2% | 567,542 | 6.22 |
| 2025-03-31 | 3,722,765 | +7.0% | 419,344 | 8.88 |
| 2025-03-14 | 3,478,901 | -9.1% | 590,201 | 5.89 |
| 2025-02-28 | 3,827,260 | -1.3% | 621,976 | 6.15 |
| 2025-02-14 | 3,878,991 | +2.0% | 303,186 | 12.79 |
| 2025-01-31 | 3,801,306 | +3.0% | 364,562 | 10.43 |
| 2025-01-15 | 3,691,876 | +3.3% | 346,523 | 10.65 |
| 2024-12-31 | 3,574,161 | +4.0% | 248,930 | 14.36 |
| 2024-12-13 | 3,437,869 | +2.5% | 270,251 | 12.72 |
| 2024-11-29 | 3,353,222 | +4.3% | 220,960 | 15.18 |
| 2024-11-15 | 3,215,971 | +7.1% | 285,354 | 11.27 |
| 2024-10-31 | 3,002,392 | +0.3% | 166,122 | 18.07 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of AORT volume is 56.8%, down 0.1 points over the last five sessions. Over the last 30 readings it ranged from 36.0% (8 October 2026) to 81.8% (16 October 2026). The latest reading is 3.7 points below the 30-session average of 60.4%, on 259K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 147K | 259K | 56.8% | 0 |
| 2026-11-02 | 176K | 255K | 69.1% | 0 |
| 2026-10-30 | 126K | 208K | 60.4% | 0 |
| 2026-10-29 | 62K | 119K | 52.1% | 0 |
| 2026-10-28 | 83K | 153K | 54.0% | 0 |
| 2026-10-27 | 64K | 113K | 56.8% | 0 |
| 2026-10-26 | 83K | 137K | 60.9% | 0 |
| 2026-10-23 | 70K | 123K | 57.0% | 0 |
| 2026-10-22 | 133K | 186K | 71.5% | 0 |
| 2026-10-21 | 79K | 132K | 60.0% | 0 |
| 2026-10-20 | 115K | 181K | 63.4% | 0 |
| 2026-10-19 | 116K | 158K | 73.5% | 0 |
| 2026-10-16 | 152K | 185K | 81.8% | 0 |
| 2026-10-15 | 145K | 209K | 69.2% | 133 |
| 2026-10-14 | 133K | 166K | 80.1% | 0 |
| 2026-10-13 | 162K | 281K | 57.7% | 0 |
| 2026-10-12 | 71K | 140K | 50.7% | 0 |
| 2026-10-09 | 53K | 97K | 55.3% | 0 |
| 2026-10-08 | 57K | 159K | 36.0% | 0 |
| 2026-10-07 | 48K | 85K | 56.1% | 0 |
| 2026-10-06 | 101K | 184K | 54.6% | 0 |
| 2026-10-05 | 174K | 297K | 58.7% | 0 |
| 2026-10-02 | 138K | 204K | 67.5% | 796 |
| 2026-10-01 | 97K | 140K | 69.5% | 2 |
| 2026-09-30 | 122K | 185K | 66.3% | 200 |
| 2026-09-29 | 71K | 116K | 61.3% | 0 |
| 2026-09-28 | 90K | 153K | 58.5% | 0 |
| 2026-09-25 | 87K | 200K | 43.4% | 0 |
| 2026-09-24 | 115K | 213K | 54.2% | 0 |
| 2026-09-23 | 102K | 182K | 56.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in AORT is 61 shares, down 2,381 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (3 August 2026) to 85,352 shares (20 February 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 61 | $21.21 | $1K |
| 2026-09-25 | 2,442 | $23.03 | $56K |
| 2026-09-11 | 1,570 | $24.65 | $39K |
| 2026-08-28 | 3,539 | $26.67 | $94K |
| 2026-08-26 | 34 | $26.38 | $897 |
| 2026-08-20 | 165 | $28.82 | $5K |
| 2026-08-19 | 409 | $28.90 | $12K |
| 2026-08-14 | 153 | $28.41 | $4K |
| 2026-08-03 | 2 | $26.83 | $54 |
| 2026-07-22 | 203 | $24.94 | $5K |
| 2026-07-01 | 186 | $22.47 | $4K |
| 2026-06-26 | 3 | $22.66 | $68 |
| 2026-06-18 | 70 | $21.20 | $1K |
| 2026-06-16 | 6 | $21.07 | $126 |
| 2026-06-15 | 1,649 | $20.10 | $33K |
| 2026-06-12 | 182 | $20.60 | $4K |
| 2026-06-02 | 355 | $21.05 | $7K |
| 2026-05-19 | 170 | $23.76 | $4K |
| 2026-04-08 | 121 | $35.22 | $4K |
| 2026-03-25 | 2,665 | $35.70 | $95K |
| 2026-03-23 | 8 | $35.31 | $282 |
| 2026-03-17 | 16,174 | $37.40 | $605K |
| 2026-03-06 | 27 | $37.86 | $1K |
| 2026-02-20 | 85,352 | $38.00 | $3.2M |
| 2026-01-05 | 40 | $44.46 | $2K |
| 2025-12-26 | 195 | $46.89 | $9K |
| 2025-12-04 | 15,315 | $45.48 | $697K |
| 2025-11-17 | 2,941 | $45.70 | $134K |
| 2025-11-14 | 2,942 | $45.59 | $134K |
| 2025-10-30 | 732 | $44.99 | $33K |
Insider trades
SEC Form 4, newest first. JSONInsiders at AORT reported 7 open-market sells worth $2.6M in the last 90 days and no open-market buys. Latest filing: GREEN ANDREW M (SVP, Regulatory and Quality) on 2026-09-10.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-10 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 11K | $24.97 | $287K | 40K |
| 2026-09-03 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 1K | $26.02 | $39K | 52K |
| 2026-09-02 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 7K | $27.27 | $177K | 53K |
| 2026-08-19 | Mackin James P | President & CEO | Sell | 70K | $28.95 | $2.0M | 877K |
| 2026-08-14 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 616 | $28.55 | $18K | 60K |
| 2026-08-14 | Berry Lance A | EVP, COO, CFO & Treasurer | Sell | 715 | $28.55 | $20K | 210K |
| 2026-08-12 | Holloway Jean F | SVP, General Counsel | Sell | 977 | $28.49 | $28K | 184K |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 30K | $20.69 | $621K | 60K |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Exercise or conversion | 30K | $11.03 | $331K | 90K |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Sell | 14K | $20.71 | $290K | 60K |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Exercise or conversion | 14K | $18.44 | $258K | 74K |
| 2026-06-02 | SEMEDO ANTHONY B. | Director | Other transaction | 6K | $0.00 | $0 | 6K |
| 2026-06-02 | SEMEDO ANTHONY B. | Director | Other transaction | 6K | $0.00 | $0 | 41K |
| 2026-05-18 | Borgstrom Marna P | Director | Grant | 8K | $0.00 | $0 | 57K |
| 2026-05-18 | SEMEDO ANTHONY B. | Director | Grant | 8K | $0.00 | $0 | 47K |
| 2026-05-18 | Salveson Jon W | Director | Grant | 8K | $0.00 | $0 | 137K |
| 2026-05-18 | Hoff Elizabeth A | Director | Grant | 8K | $0.00 | $0 | 35K |
| 2026-05-18 | Burbank Jeffrey H | Director | Grant | 8K | $0.00 | $0 | 61K |
| 2026-05-18 | Bullock James | Director | Grant | 8K | $0.00 | $0 | 76K |
| 2026-05-18 | BEVEVINO DANIEL J | Director | Grant | 8K | $0.00 | $0 | 158K |
| 2026-05-18 | ACKERMAN THOMAS F | Director | Grant | 8K | $0.00 | $0 | 157K |
| 2026-05-14 | Borgstrom Marna P | Director | Grant | 8K | $0.00 | $0 | 57K |
| 2026-03-04 | Holloway Jean F | SVP, General Counsel | Sell | 9K | $38.00 | $341K | 185K |
| 2026-03-03 | Horton Amy | VP, Chief Accounting Officer | Sell | 901 | $37.78 | $34K | 139K |
| 2026-03-03 | Holloway Jean F | SVP, General Counsel | Sell | 4K | $37.78 | $145K | 194K |
| 2026-03-03 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 2K | $37.78 | $81K | 60K |
| 2026-03-03 | Davis John E | Chief Commercial Officer | Sell | 5K | $37.78 | $173K | 231K |
| 2026-03-03 | Berry Lance A | EVP, COO, CFO & Treasurer | Sell | 6K | $37.78 | $239K | 211K |
| 2026-03-03 | Mackin James P | President & CEO | Sell | 18K | $37.78 | $676K | 947K |
| 2026-03-02 | Horton Amy | VP, Chief Accounting Officer | Sell | 641 | $38.02 | $24K | 133K |
| 2026-03-02 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 2K | $38.02 | $58K | 40K |
| 2026-03-02 | Mackin James P | President & CEO | Sell | 15K | $38.02 | $567K | 848K |
| 2026-03-02 | Holloway Jean F | SVP, General Counsel | Sell | 2K | $38.02 | $83K | 170K |
| 2026-03-02 | Berry Lance A | EVP, COO, CFO & Treasurer | Sell | 5K | $38.02 | $197K | 176K |
| 2026-03-02 | Davis John E | Chief Commercial Officer | Sell | 3K | $38.02 | $106K | 207K |
| 2026-03-02 | Horton Amy | VP, Chief Accounting Officer | Grant | 7K | $0.00 | $0 | 140K |
| 2026-03-02 | Holloway Jean F | SVP, General Counsel | Grant | 28K | $0.00 | $0 | 198K |
| 2026-03-02 | Stanton Marshall S. | SVP, Clinical & MD Affair | Grant | 22K | $0.00 | $0 | 62K |
| 2026-03-02 | Davis John E | Chief Commercial Officer | Grant | 29K | $0.00 | $0 | 235K |
| 2026-03-02 | Berry Lance A | EVP, COO, CFO & Treasurer | Grant | 41K | $0.00 | $0 | 217K |
| 2026-03-02 | Mackin James P | President & CEO | Grant | 117K | $0.00 | $0 | 965K |
| 2026-02-24 | Horton Amy | VP, Chief Accounting Officer | Grant | 6K | $0.00 | $0 | 133K |
| 2026-02-24 | Horton Amy | VP, Chief Accounting Officer | Sell | 830 | $35.69 | $30K | 127K |
| 2026-02-24 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 1K | $35.69 | $45K | 42K |
| 2026-02-24 | Holloway Jean F | SVP, General Counsel | Grant | 20K | $0.00 | $0 | 172K |
| 2026-02-24 | Holloway Jean F | SVP, General Counsel | Sell | 2K | $35.69 | $60K | 152K |
| 2026-02-24 | Mackin James P | President & CEO | Grant | 97K | $0.00 | $0 | 863K |
| 2026-02-24 | Mackin James P | President & CEO | Sell | 14K | $35.69 | $497K | 766K |
| 2026-02-24 | Berry Lance A | EVP, COO, CFO & Treasurer | Grant | 37K | $0.00 | $0 | 181K |
| 2026-02-24 | Berry Lance A | EVP, COO, CFO & Treasurer | Sell | 4K | $35.69 | $160K | 144K |
| 2026-02-24 | Davis John E | Chief Commercial Officer | Grant | 20K | $0.00 | $0 | 209K |
| 2026-02-24 | Davis John E | Chief Commercial Officer | Sell | 2K | $35.69 | $74K | 189K |
| 2026-02-23 | Horton Amy | VP, Chief Accounting Officer | Sell | 2K | $37.59 | $65K | 128K |
| 2026-02-23 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 2K | $37.59 | $91K | 43K |
| 2026-02-23 | Holloway Jean F | SVP, General Counsel | Sell | 3K | $37.59 | $116K | 154K |
| 2026-02-23 | Mackin James P | President & CEO | Sell | 21K | $37.59 | $788K | 780K |
| 2026-02-23 | Berry Lance A | EVP, COO, CFO & Treasurer | Sell | 5K | $37.59 | $187K | 148K |
| 2026-02-23 | Davis John E | Chief Commercial Officer | Sell | 4K | $37.59 | $142K | 191K |
| 2025-12-15 | Davis John E | Chief Commercial Officer | Sell | 5K | $45.11 | $226K | 194K |
| 2025-12-08 | Horton Amy | VP, Chief Accounting Officer | Sell | 5K | $44.42 | $203K | 130K |
| 2025-12-03 | Mackin James P | President & CEO | Sell | 31K | $45.46 | $1.4M | 801K |
| 2025-12-03 | Mackin James P | President & CEO | Exercise or conversion | 31K | $29.62 | $916K | 832K |
| 2025-12-03 | Holloway Jean F | SVP, General Counsel | Sell | 5K | $45.30 | $239K | 156K |
| 2025-12-03 | Holloway Jean F | SVP, General Counsel | Sell | 2K | $45.30 | $93K | 161K |
| 2025-12-02 | Mackin James P | President & CEO | Sell | 31K | $45.56 | $1.4M | 801K |
| 2025-12-02 | Mackin James P | President & CEO | Exercise or conversion | 31K | $29.62 | $916K | 832K |
| 2025-12-01 | Horton Amy | VP, Chief Accounting Officer | Gift | 750 | $0.00 | $0 | 135K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 8K | $45.34 | $380K | 45K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 19K | $44.91 | $840K | 53K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Exercise or conversion | 27K | $11.03 | $299K | 72K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 6K | $45.35 | $259K | 45K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 15K | $44.92 | $655K | 50K |
| 2025-11-21 | Stanton Marshall S. | SVP, Clinical & MD Affair | Exercise or conversion | 20K | $18.44 | $374K | 65K |
| 2025-11-20 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 1K | $44.28 | $60K | 45K |
| 2025-11-20 | Stanton Marshall S. | SVP, Clinical & MD Affair | Exercise or conversion | 1K | $11.03 | $15K | 46K |
| 2025-11-20 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 2K | $44.31 | $90K | 45K |
| 2025-11-20 | Stanton Marshall S. | SVP, Clinical & MD Affair | Exercise or conversion | 2K | $18.44 | $37K | 47K |
| 2025-11-20 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 12K | $44.14 | $525K | 45K |
| 2025-11-18 | Hoff Elizabeth A | Director | Sell | 4K | $45.10 | $189K | 27K |
| 2025-11-17 | Holloway Jean F | SVP, General Counsel | Sell | 6K | $45.17 | $289K | 163K |
| 2025-11-17 | Holloway Jean F | SVP, General Counsel | Exercise or conversion | 6K | $29.62 | $189K | 170K |
| 2025-11-17 | Davis John E | Chief Commercial Officer | Sell | 6K | $45.17 | $289K | 199K |
| 2025-11-17 | Davis John E | Chief Commercial Officer | Exercise or conversion | 6K | $29.62 | $189K | 205K |
| 2025-11-17 | Horton Amy | VP, Chief Accounting Officer | Sell | 6K | $45.73 | $274K | 135K |
| 2025-11-14 | Holloway Jean F | SVP, General Counsel | Sell | 6K | $45.00 | $288K | 163K |
| 2025-11-14 | Holloway Jean F | SVP, General Counsel | Exercise or conversion | 6K | $29.62 | $189K | 170K |
| 2025-11-14 | Davis John E | Chief Commercial Officer | Sell | 6K | $44.67 | $286K | 199K |
| 2025-11-14 | Davis John E | Chief Commercial Officer | Exercise or conversion | 6K | $29.62 | $189K | 205K |
| 2025-11-13 | Horton Amy | VP, Chief Accounting Officer | Sell | 3K | $45.86 | $160K | 141K |
| 2025-11-13 | Davis John E | Chief Commercial Officer | Sell | 7K | $45.86 | $301K | 199K |
| 2025-11-13 | Mackin James P | President & CEO | Sell | 34K | $45.86 | $1.6M | 801K |
| 2025-11-13 | Holloway Jean F | SVP, General Counsel | Sell | 6K | $45.86 | $264K | 163K |
| 2025-11-13 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 5K | $45.86 | $229K | 57K |
| 2025-11-11 | Holloway Jean F | SVP, General Counsel | Sell | 10K | $46.18 | $462K | 169K |
| 2025-11-11 | Holloway Jean F | SVP, General Counsel | Exercise or conversion | 10K | $11.03 | $110K | 179K |
| 2025-11-10 | Holloway Jean F | SVP, General Counsel | Sell | 3K | $44.62 | $132K | 169K |
| 2025-11-10 | Mackin James P | President & CEO | Sell | 18K | $44.62 | $784K | 835K |
| 2025-11-10 | Davis John E | Chief Commercial Officer | Sell | 3K | $44.62 | $150K | 205K |
| 2025-11-10 | Horton Amy | VP, Chief Accounting Officer | Sell | 2K | $44.62 | $80K | 145K |
| 2025-11-10 | Stanton Marshall S. | SVP, Clinical & MD Affair | Sell | 3K | $44.62 | $114K | 62K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for AORT worth $18.9M at the prices reported; 7 in the last 90 days worth $2.8M. Latest: GREEN ANDREW M filed on 2026-09-10 to sell 11,480 shares ($287K) from 2026-09-10.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-10 | GREEN ANDREW MOfficer | 11K | $287K | 0.024% | 2026-09-10 | Fidelity Brokerage Services LLC |
| 2026-09-03 | GREEN ANDREW MOfficer | 1K | $39K | 0.003% | 2026-09-03 | Fidelity Brokerage Services LLC |
| 2026-09-02 | GREEN ANDREW MOfficer | 7K | $177K | 0.013% | 2026-09-02 | Fidelity Brokerage Services LLC |
| 2026-08-27 | Stanton Marshall S.Officer | 7K | $199K | 0.015% | 2026-08-27 | Fidelity Brokerage Services LLC |
| 2026-08-19 | Mackin James POfficer | 70K | $2.1M | 0.144% | 2026-08-19 | Fidelity Investments |
| 2026-08-14 | Berry Lance AOfficer | 715 | $20K | 0.001% | 2026-08-14 | Fidelity Brokerage Services LLC |
| 2026-08-14 | GREEN ANDREW MOfficer | 616 | $18K | 0.001% | 2026-08-14 | Fidelity Brokerage Services LLC |
| 2026-06-11 | GREEN ANDREW MOfficer | 44K | $911K | 0.091% | 2026-06-11 | Fidelity Brokerage Services LLC |
| 2026-03-04 | JEAN F HOLLOWAYOfficer | 9K | $341K | 0.019% | 2026-03-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | Berry Lance AOfficer | 6K | $239K | 0.013% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Davis John EOfficer | 5K | $173K | 0.010% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Holloway Jean FOfficer | 4K | $145K | 0.008% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Stanton Marshall S.Officer | 2K | $81K | 0.004% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Mackin James POfficer, Director | 18K | $676K | 0.037% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-03 | Horton AmyOfficer | 901 | $34K | 0.002% | 2026-03-03 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Holloway Jean FOfficer | 2K | $83K | 0.005% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Mackin James POfficer, Director | 15K | $567K | 0.031% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Davis John EOfficer | 3K | $106K | 0.006% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Horton AmyOfficer | 641 | $24K | 0.001% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Berry Lance AOfficer | 5K | $197K | 0.011% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Stanton Marshall S.Officer | 2K | $58K | 0.003% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Davis John EOfficer | 2K | $74K | 0.004% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Berry Lance AOfficer | 4K | $160K | 0.009% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Holloway Jean FOfficer | 2K | $60K | 0.003% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Mackin James POfficer, Director | 14K | $497K | 0.029% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Stanton Marshall S.Officer | 1K | $45K | 0.003% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Horton AmyOfficer | 830 | $30K | 0.002% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Horton AmyOfficer | 2K | $65K | 0.004% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Mackin James POfficer, Director | 21K | $788K | 0.044% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Holloway Jean FOfficer | 3K | $116K | 0.006% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Davis John EOfficer | 4K | $142K | 0.008% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Berry Lance AOfficer | 5K | $187K | 0.010% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Stanton Marshall S.Officer | 2K | $91K | 0.005% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2025-12-17 | Davis John EOfficer | 5K | $226K | 0.011% | 2025-12-15 | CHARLES SCHWAB |
| 2025-12-08 | Horton AmyOfficer | 5K | $203K | 0.010% | 2025-12-08 | Fidelity Brokerage Services LLC |
| 2025-12-03 | Mackin James POfficer, Director | 31K | $1.4M | 0.065% | 2025-12-03 | Fidelity Brokerage Services LLC |
| 2025-12-03 | JEAN F HOLLOWAYOfficer | 7K | $331K | 0.015% | 2025-12-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-02 | Mackin James POfficer, Director | 31K | $1.4M | 0.065% | 2025-12-02 | Fidelity Brokerage Services LLC |
| 2025-11-21 | Stanton Marshall S.Officer | 47K | $2.1M | 0.100% | 2025-11-21 | Fidelity Brokerage Services LLC |
| 2025-11-20 | Stanton Marshall S.Officer | 15K | $675K | 0.032% | 2025-11-20 | Fidelity Brokerage Services LLC |
| 2025-11-18 | ELIZABETH A HOFFDirector | 4K | $189K | 0.009% | 2025-11-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | Davis John EOfficer | 6K | $289K | 0.013% | 2025-11-17 | Fidelity Brokerage Services LLC |
| 2025-11-17 | Horton AmyOfficer | 6K | $274K | 0.013% | 2025-11-17 | Fidelity Brokerage Services LLC |
| 2025-11-17 | Holloway Jean FOfficer | 6K | $289K | 0.013% | 2025-11-17 | Fidelity Brokerage Services LLC |
| 2025-11-14 | Holloway Jean FOfficer | 6K | $288K | 0.013% | 2025-11-14 | Fidelity Brokerage Services LLC |
| 2025-11-14 | Davis John EOfficer | 6K | $286K | 0.013% | 2025-11-14 | Fidelity Brokerage Services LLC |
| 2025-11-13 | Horton AmyOfficer | 3K | $160K | 0.007% | 2025-11-13 | Fidelity Brokerage Services LLC |
| 2025-11-13 | Holloway Jean FOfficer | 6K | $264K | 0.012% | 2025-11-13 | Fidelity Brokerage Services LLC |
| 2025-11-13 | Mackin James POfficer, Director | 34K | $1.6M | 0.072% | 2025-11-13 | Fidelity Brokerage Services LLC |
| 2025-11-13 | Stanton Marshall S.Officer | 5K | $229K | 0.011% | 2025-11-13 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON3 holders report 5% or more of AORT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 14.7% of the class (7,159,279 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 6 | BlackRock, Inc.parent holding company | 7.2M | 14.7% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 1 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC.parent holding company | 3.2M | 6.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | NOMURA INVESTMENT MANAGEMENT BUSINESS TRUSTinvestment adviser | 3.2M | 6.5% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 2 | FMR LLCparent holding company | 2.0M | 4.0% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 2.0M | 4.0% | 2026-06-30 |
| 2026-03-26 | 13G/Ano. 6 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 7 | Macquarie Group Limitedparent holding company | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 7 | Macquarie Management Holdings Incparent holding company | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 7 | Macquarie Investment Management Business Trustinvestment adviser | 0 | 0.0% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 2.0M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Joseph Edelmanindividual | 2.0M | 4.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 2.0M | 4.3% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 2 | Morgan Stanleyparent holding company, corporation | 2.1M | 4.4% | 2025-09-30 |
13F holders
Tracked managers holding AORT at their latest 13F. JSON5 of the 30 tracked managers held AORT at their latest 13F, $39.0M in total at quarter-end prices. Citadel Advisors is the largest at $18.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 828K | $18.6M | 0.00% | +757K |
| D. E. Shaw & Co. | 2026-06-30 | 438K | $9.8M | 0.00% | +432K |
| Two Sigma Investments | 2026-06-30 | 387K | $8.7M | 0.01% | -339K |
| Renaissance Technologies | 2026-06-30 | 68K | $1.5M | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 14K | $323K | 0.00% | -4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Artivion reported revenue of $125.8M, up 11.3% from the same quarter a year earlier, and net loss of $13.5M (-0.28 diluted EPS). In FY 2025 it generated $39.9M of operating cash flow. As of 2026-06-30, cash was $77.3M against $363.4M of debt.
- Cash
- $77.3M
- Debt
- $363.4M
- Equity
- $445.6M
- Total assets
- $1.07B
- Shares outstanding
- 48,756,221
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $125.8M | -$13.5M | -10.7% | -0.28 |
| Q1 FY 2026 | 2026-03-31 | $116.3M | $1.4M | 1.2% | 0.03 |
| Q4 FY 2025derived | 2025-12-31 | $116.0M | $2.4M | 2.1% | n/a |
| Q3 FY 2025 | 2025-09-30 | $113.4M | $6.5M | 5.7% | 0.13 |
| Q2 FY 2025 | 2025-06-30 | $113.0M | $1.3M | 1.2% | 0.03 |
| Q1 FY 2025 | 2025-03-31 | $99.0M | -$505K | -0.5% | -0.01 |
| Q4 FY 2024derived | 2024-12-31 | $97.3M | -$16.5M | -16.9% | n/a |
| Q3 FY 2024 | 2024-09-30 | $95.8M | -$2.3M | -2.4% | -0.05 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $441.3M | $9.8M | $39.9M | $39.0M | n/a | n/a |
| FY 2024 | 2024-12-31 | $388.5M | -$13.4M | $22.2M | $11.2M | n/a | n/a |
| FY 2023 | 2023-12-31 | $354.0M | -$30.7M | $18.8M | $9.8M | n/a | n/a |
| FY 2022 | 2022-12-31 | $313.8M | -$19.2M | -$5.2M | $10.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $298.8M | -$14.8M | -$2.6M | $13.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Artivion in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Artivion (AORT), SEC CIK 784199, listed on NYSE, classified by the SEC as surgical & medical instruments & apparatus. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-10.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-10.JSON and CSV
- Company record
- EDGAR filing index for CIK 784199Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as surgical & medical instruments & apparatus
Other company pages
Datasets
Frequently Asked Questions
How much of AORT is sold short?
3,735,523 shares were held short at the 2026-10-15 settlement, 7.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AORT's daily short volume?
On 2026-11-03, 146,879 of the 258,797 AORT shares reported to FINRA were sold short, 56.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AORT have fails to deliver?
The SEC's latest file shows 61 AORT shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are AORT insiders buying or selling?
Insiders at AORT reported 7 open-market sells worth $2.6M in the last 90 days and no open-market buys. Latest filing: GREEN ANDREW M (SVP, Regulatory and Quality) on 2026-09-10.
Have AORT insiders filed to sell?
50 Form 144 notices on file for AORT worth $18.9M at the prices reported; 7 in the last 90 days worth $2.8M. Latest: GREEN ANDREW M filed on 2026-09-10 to sell 11,480 shares ($287K) from 2026-09-10.
Who owns 5% or more of AORT?
3 holders report 5% or more of AORT in their latest filing, all on Schedule 13G (passive). The largest reported stake is BlackRock, Inc. at 14.7% of the class (7,159,279 shares), filed 2026-10-27 for an event on 2026-09-30.
What did AORT report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Artivion reported revenue of $125.8M, up 11.3% from the same quarter a year earlier, and net loss of $13.5M (-0.28 diluted EPS). In FY 2025 it generated $39.9M of operating cash flow. As of 2026-06-30, cash was $77.3M against $363.4M of debt.
Which tracked 13F managers own AORT?
5 of the 30 tracked 13F managers held AORT shares at their latest filing, $39.0M in all. The largest: Ken Griffin's Citadel Advisors (828K shares, $18.6M), D. E. Shaw & Co. (438K shares, $9.8M), Two Sigma Investments (387K shares, $8.7M), Renaissance Technologies (68K shares, $1.5M), Cliff Asness's AQR Capital Management (14K shares, $323K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.